GU medical oncologist & clinical trialist at CU Anschutz | Director, Clinical GU Research Program | Prostate cancer research | Endurance athlete
University of Colorado
Joined June 2026
- Tweets11
- Following50
- Followers6
- Likes12
Thanks, Mark! Enjoyed presenting these first clinical data exploring tumor-targeted CD28 costimulation alongside CD3 directed T cell engagement. Grateful for the collaborative effort from the J&J team, investigators, and especially the patients who made this research possible!
At #ESMO26 we introduced a new word, #RIPTAC, JNJ-6143. Introducing another innovation presented @sitcancer yesterday! FIH Investigational combo of Pasritamig our @JNJInnovMed KLK2xCD3 T-cell agent + our PSMA x CD28 co-stim JNJ-9401. Signal 1 & signal 2 together! #MyCompany
Laura Graham retweeted
Dual-antigen T-cell engagement demonstrates encouraging clinical activity in advanced prostate cancer.
At #SITC26, Laura Graham, MD of @CUDeptMedicine presents phase 1 results showing substantial PSA reductions and a manageable safety profile with combined KLK2 and PSMA targeting. #MoffittSITC26
Thank you @sitcancer for the opportunity to share our work at #SITC26! It was a privilege to present these exciting early data and be part of such a fantastic meeting. Grateful to all the patients and collaborators who made this research possible! @drmnstein @CUCancerCenter
Thanks @LauraGrahamMD for a great presentation at #SITC26. Groundbreaking research is always the case at a @sitcancer Annual Meeting!
Encouraging safety at the recommended regimen: no grade ≥3 treatment-related AEs; 20% CRS, all grade 1.
Grateful to the patients, investigators, and study team who made this work possible!
Excited to see this approach move forward in phase 3. #SITC2026
Grateful to @drmnstein for his mentorship, collaboration, and leadership throughout this study. A privilege to work with such an outstanding team and help bring these exciting data to SITC!
Great to speak with @OncLive about our #SITC2026 data combining KLK2×CD3 T-cell engagement with PSMA×CD28 costimulation in #mCRPC.
Encouraging early results with deep, durable PSA responses and favorable safety profile. Excited about the potential of this approach!
WATCH: @LauraGrahamMD of @CUAnschutz discusses safety and efficacy data for JNJ-87189401 plus pasritamig in mCRPC @sitcancer #SITC26 #pcsm #oncology
onclive.com/view/dr-graham-o…
Great chatting with @OncLive about our upcoming #SITC26 presentation!
Excited to share our first-in-human phase 1 results combining PSMA×CD28 costimulation with KLK2×CD3 T-cell engagement in #mCRPC.
Looking forward to tomorrow's presentation!
Thank you to @LauraGrahamMD of @CUCancerCenter
for stopping by to discuss her @sitcancer
presentation on phase 1 data for the PSMAxCD28 T-cell engager JNJ-87189401 plus pasritamig in mCRPC.
Stay tuned for her presentation on Saturday at #SITC26!
I’ll be presenting our late-breaking phase 1 results of JNJ-87189401 (PSMA×CD28) + pasritamig (KLK2×CD3) at #SITC26.
Nov 7 | 1:45 p.m. MST
Abstract #1175 |
Looking forward to connecting!
sitcancer.org/2026/schedule/…
#ProstateCancer #Immunotherapy
Grateful to receive the 2026 Quintin Family Foundation–PCF Young Investigator Award, supporting our T-REX research in advanced prostate cancer. Thank you to PCF the Quintin Family Foundation, and my mentors Thomas Flaig, Lawrence Fong, and Mark Stein!
@PCFnews #ProstateCancer
